Edition:
India

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

112.08USD
29 Apr 2016
Change (% chg)

$-0.40 (-0.36%)
Prev Close
$112.48
Open
$112.06
Day's High
$112.22
Day's Low
$111.51
Volume
3,600,845
Avg. Vol
2,929,704
52-wk High
$114.19
52-wk Low
$81.79

JNJ.N

Chart for JNJ.N

About

Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Company’s primary focus is products related to human health and... (more)

Overall

Beta: 0.58
Market Cap(Mil.): $309,155.31
Shares Outstanding(Mil.): 2,758.34
Dividend: 0.80
Yield (%): 2.86

Financials

  JNJ.N Industry Sector
P/E (TTM): 20.43 34.16 45.44
EPS (TTM): 5.49 -- --
ROI: -- 13.08 12.53
ROE: -- 13.78 13.40
Search Stocks

J&J shares hit new high on strong drug sales, weaker dollar

Johnson & Johnson beat quarterly earnings forecasts on strong prescription drug revenue and a weakening dollar, and it reassured investors that it did not expect its blockbuster Remicade arthritis drug to face U.S. competition this year.

19 Apr 2016

J&J shares hit new high on strong drug sales, weaker dollar

Johnson & Johnson beat quarterly earnings forecasts on strong prescription drug revenue and a weakening dollar, and it reassured investors that it did not expect its blockbuster Remicade arthritis drug to face U.S. competition this year.

19 Apr 2016

UPDATE 3-J&J shares hit new high on strong drug sales, weaker dollar

April 19 Johnson & Johnson beat quarterly earnings forecasts on strong prescription drug revenue and a weakening dollar, and it reassured investors that it did not expect its blockbuster Remicade arthritis drug to face U.S. competition this year.

19 Apr 2016

J&J first-quarter sales rise marginally

April 19 Johnson & Johnson reported a 0.6 percent rise in first-quarter sales, constrained by the strong dollar and Venezuela's currency devaluation.

19 Apr 2016

What to Watch in the Day Ahead - Tuesday, April 19

(The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at . Thomson One users can register at RT/DAY/US. All times in ET/GMT) Johnson & Johnson is expected to report moderately higher earnings as it kicks off the first-quarter earnings season for large U.S. drugmakers, bolstered by cost cuts and growing sales of its treatments for cancer, arthritis and psoriasis. But investo

19 Apr 2016

Investors find safety in J&J shares, but run could stall

NEW YORK, April 14 After lagging a six-year healthcare sector run fueled by fast-growing biotech companies, Johnson & Johnson shares have beaten the group in 2016 as investors turn to safety in rocky equity markets.

14 Apr 2016

FDA approves tissue container for laparoscopic device

April 7 The U.S. Food and Drug Administration approved a tissue container bag for use in certain laparoscopic procedures along with power morcellators, that have been linked to the spread of cancer in women.

08 Apr 2016

Factbox: Price hikes shore up revenue for top-selling U.S. drugs

NEW YORK Hefty price increases bolstered revenues for manufacturers even as prescriptions declined over the past five years. Below is a breakdown for the top 10 drugs by U.S. sales, based on the most recently available data from IMS Health and interviews with price experts.

04 Apr 2016

EU recommends conditional approval of J&J's blood cancer drug

European regulators on Friday recommended approving with conditions Johnson & Johnson's blood cancer drug, saying they would need to evaluate additional data from two ongoing studies.

01 Apr 2016

UPDATE 2-EU recommends conditional approval of J&J's blood cancer drug

April 1 European regulators on Friday recommended approving with conditions Johnson & Johnson's blood cancer drug, saying they would need to evaluate additional data from two ongoing studies.

01 Apr 2016

Earnings vs. Estimates

Search Stocks